Continued execution of BioNTech’s oncology strategy with focus on two pan-tumor programs including two announced transactions: mRNA-based cancer immunotherapy candidates and BNT327, a bispecific antib ...

FRANKFURT (Reuters) -German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 ...